Skip to main content

01.04.2024

Understanding and Treating Dual Diagnosis: Double the Trouble

verfasst von: Victor M. Tang, Tony P. George

Erschienen in: Current Addiction Reports

Einloggen, um Zugang zu erhalten

Excerpt

In this Topical Collection of Current Addiction Reports, we discuss the results of five review articles in the field of dual diagnosis—the co-morbidity of substance misuse and psychiatric disorders. This is an important clinical and academic area of investigation, which unfortunately continues to be understudied and underfunded in our fields of psychiatry and addictions. Patients who report both mental illness and substance use disorder represent ~ 8.4% of the general population, based on the recent National Survey of Drug Use and Health (NSDUH; [1]). There are many reasons for this disparity in comparison to either substance use disorders (SUDs) or psychiatric disorders alone. Studies of dual diagnosis are difficult to conduct given the clinical complexities of these populations, as well as the limited feasibility of recruiting and retaining these participants in clinical studies. Accordingly, many investigators do not invest their time in studying such “difficult” populations. This, unfortunately, has produced a substantial knowledge gap, which is very problematic since dual diagnosis represents the external reality of clinical populations in hospitals and the community. For the treatment of schizophrenia, there is evidence to suggest that antipsychotic treatment effects may be lower in real-world settings compared to RCTs, given that RCTs typically exclude patients that are more complex but representative of typical clinical presentations [2]. Similarly, patients who present with dual diagnoses have poorer treatment outcomes compared to those with single diagnoses [3] and contribute to a larger burden on the healthcare system [4]. The presence of psychiatric symptoms in those receiving SUD treatment is more likely to relapse compared to those who do not have psychiatric symptoms [5]. Therefore, research specifically into how we can best approach the management of dual diagnoses is of critical importance. Accordingly, this Topical Collection attempts to shed light on the complexities of dual diagnosis and highlights clinical assessment and treatment options available to dually diagnosed patients. …
Literatur
1.
Zurück zum Zitat SAMSHA. Key substance use and mental health indicators in the United States: results from the 2022 national survey on drug use and health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for behavioral health statistics and quality, substance abuse and mental health services administration. 2022. SAMSHA. Key substance use and mental health indicators in the United States: results from the 2022 national survey on drug use and health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58). Center for behavioral health statistics and quality, substance abuse and mental health services administration. 2022.
2.
Zurück zum Zitat Efthimiou O, Taipale H, Radua J, Schneider-Thoma J, Pinzón-Espinosa J, Ortuño M et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. The Lancet Psychiatry. 2024;11:102–11. Efthimiou O, Taipale H, Radua J, Schneider-Thoma J, Pinzón-Espinosa J, Ortuño M et al. Efficacy and effectiveness of antipsychotics in schizophrenia: network meta-analyses combining evidence from randomised controlled trials and real-world data. The Lancet Psychiatry. 2024;11:102–11.
3.
Zurück zum Zitat Hjorthøj C, Østergaard ML, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, Nordentoft M. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. The Lancet Psychiatry. 2015;2:801–8. Hjorthøj C, Østergaard ML, Benros ME, Toftdahl NG, Erlangsen A, Andersen JT, Nordentoft M. Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. The Lancet Psychiatry. 2015;2:801–8.
4.
Zurück zum Zitat Chen LY, Crum RM, Martins S, Kaufmann CN, Strain EC, Mojtabai R. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv. 2013;64:863–70.CrossRefPubMedPubMedCentral Chen LY, Crum RM, Martins S, Kaufmann CN, Strain EC, Mojtabai R. Service use and barriers to mental health care among adults with major depression and comorbid substance dependence. Psychiatr Serv. 2013;64:863–70.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, Hasin D. Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addiction. 2013;108(1):115–23.CrossRefPubMed Samet S, Fenton MC, Nunes E, Greenstein E, Aharonovich E, Hasin D. Effects of independent and substance-induced major depressive disorder on remission and relapse of alcohol, cocaine and heroin dependence. Addiction. 2013;108(1):115–23.CrossRefPubMed
6.
Zurück zum Zitat Myran DT, Harrison LD, Pugliease M, Solmi M, Anderson KK, Fiedorowicz JG, et al. Transition to schizophrenia spectrum disorder following emergency department visits due to substance use with and without psychosis. JAMA Psychiat. 2023;80:1169–74.CrossRef Myran DT, Harrison LD, Pugliease M, Solmi M, Anderson KK, Fiedorowicz JG, et al. Transition to schizophrenia spectrum disorder following emergency department visits due to substance use with and without psychosis. JAMA Psychiat. 2023;80:1169–74.CrossRef
7.
Zurück zum Zitat Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiat. 2015;72:1235–42.CrossRef Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiat. 2015;72:1235–42.CrossRef
8.
Zurück zum Zitat Hasin DS, Sarvet AL, Cerdá M, et al. US Adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991–1992 to 2012–2013. JAMA Psychiat. 2017;74:579–88.CrossRef Hasin DS, Sarvet AL, Cerdá M, et al. US Adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991–1992 to 2012–2013. JAMA Psychiat. 2017;74:579–88.CrossRef
9.
Zurück zum Zitat Hjorthøj C, Compton W, Starzer M, Nordholm D, Einstein E, Erlangsen A et al. Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychol Med. 2023;53:7322–8. Hjorthøj C, Compton W, Starzer M, Nordholm D, Einstein E, Erlangsen A et al. Association between cannabis use disorder and schizophrenia stronger in young males than in females. Psychol Med. 2023;53:7322–8.
10.
Zurück zum Zitat Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force report: serotonergic psychedelic treatments for major depressive disorder. Can J Psychiatry. 2023;68:5–21.CrossRefPubMed Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force report: serotonergic psychedelic treatments for major depressive disorder. Can J Psychiatry. 2023;68:5–21.CrossRefPubMed
11.
Zurück zum Zitat Starzer MSK, Nordentoft M, Hjorthøj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2018;175:343–50.CrossRefPubMed Starzer MSK, Nordentoft M, Hjorthøj C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2018;175:343–50.CrossRefPubMed
12.
Zurück zum Zitat Foulds JA, Lubman DI. Treating depression in patients with alcohol or drug use disorders: a need for clearer guidelines. Austral New Zealand J Psychiatry. 2017;51:668–9.CrossRef Foulds JA, Lubman DI. Treating depression in patients with alcohol or drug use disorders: a need for clearer guidelines. Austral New Zealand J Psychiatry. 2017;51:668–9.CrossRef
13.
Zurück zum Zitat Lucatch AM, Kloiber SM, Meyer JH, Rizvi SJ, George TP. Effects of extended cannabis abstinence in major depressive disorder. Can J Addiction. 2020;11:33–41.CrossRef Lucatch AM, Kloiber SM, Meyer JH, Rizvi SJ, George TP. Effects of extended cannabis abstinence in major depressive disorder. Can J Addiction. 2020;11:33–41.CrossRef
14.
Zurück zum Zitat George TP, Welsh L, Franchuk SL, Vaccarino FJ. Why integrating medications and psychosocial interventions is important to successfully address the opioid crisis in Canada. Can J Psychiatry. 2022;67:176–8.CrossRefPubMed George TP, Welsh L, Franchuk SL, Vaccarino FJ. Why integrating medications and psychosocial interventions is important to successfully address the opioid crisis in Canada. Can J Psychiatry. 2022;67:176–8.CrossRefPubMed
15.
Zurück zum Zitat Gatov E, Rosella L, Chiu M, Kurdyak PA. Trends in standardized mortality among individuals with schizophrenia, 1993–2012: a population-based, repeated cross-sectional study. Can Med Assoc J. 2017;189:E1177–87.CrossRef Gatov E, Rosella L, Chiu M, Kurdyak PA. Trends in standardized mortality among individuals with schizophrenia, 1993–2012: a population-based, repeated cross-sectional study. Can Med Assoc J. 2017;189:E1177–87.CrossRef
16.
Zurück zum Zitat Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, DeMeo DL, Wells JM, Make BJ, Rennard SI, Washko GR. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax. 2018;73:414–21.CrossRefPubMed Bhatt SP, Kim YI, Harrington KF, Hokanson JE, Lutz SM, Cho MH, DeMeo DL, Wells JM, Make BJ, Rennard SI, Washko GR. Smoking duration alone provides stronger risk estimates of chronic obstructive pulmonary disease than pack-years. Thorax. 2018;73:414–21.CrossRefPubMed
17.
Zurück zum Zitat Kurdyak P, Vigod S, Calzavara A, Wodchis WP. High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia. Schizophr Res. 2012;142:52–7.CrossRefPubMed Kurdyak P, Vigod S, Calzavara A, Wodchis WP. High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia. Schizophr Res. 2012;142:52–7.CrossRefPubMed
18.
Zurück zum Zitat Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.CrossRefPubMed Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.CrossRefPubMed
19.
Zurück zum Zitat Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, Savage C, Schweinfurth L, Stallings CR, Sweeney K, Yolken RH. Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. Psychiatr Serv. 2018;69(2):147–53.CrossRefPubMed Dickerson F, Schroeder J, Katsafanas E, Khushalani S, Origoni AE, Savage C, Schweinfurth L, Stallings CR, Sweeney K, Yolken RH. Cigarette smoking by patients with serious mental illness, 1999–2016: an increasing disparity. Psychiatr Serv. 2018;69(2):147–53.CrossRefPubMed
20.
Zurück zum Zitat Mehta, D.D., Praecht, A., Ward, H.B., Sanches, M., Sorkhou, M., Tang, V.M., Steele, V.R., Hanlon, C.A., George, T.P. (2024). A systematic review and meta-analysis of neuromodulation therapies for substance use disorders. Neuropsychopharmacology, 2024; In Press. Mehta, D.D., Praecht, A., Ward, H.B., Sanches, M., Sorkhou, M., Tang, V.M., Steele, V.R., Hanlon, C.A., George, T.P. (2024). A systematic review and meta-analysis of neuromodulation therapies for substance use disorders. Neuropsychopharmacology, 2024; In Press.
21.
Zurück zum Zitat Dunlop K, Hanlon CA, Downar J. Noninvasive brain stimulation treatments for addiction and major depression. Ann NY Acad Sci. 2017;1394(1):31–54.CrossRefPubMed Dunlop K, Hanlon CA, Downar J. Noninvasive brain stimulation treatments for addiction and major depression. Ann NY Acad Sci. 2017;1394(1):31–54.CrossRefPubMed
22.
Zurück zum Zitat Tang VM, Le Foll B, Blumberger DM, Voineskos D. Repetitive transcranial magnetic stimulation for comorbid major depressive disorder and alcohol use disorder. Brain Sci. 2021;30(12):48.CrossRef Tang VM, Le Foll B, Blumberger DM, Voineskos D. Repetitive transcranial magnetic stimulation for comorbid major depressive disorder and alcohol use disorder. Brain Sci. 2021;30(12):48.CrossRef
Metadaten
Titel
Understanding and Treating Dual Diagnosis: Double the Trouble
verfasst von
Victor M. Tang
Tony P. George
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Current Addiction Reports
Elektronische ISSN: 2196-2952
DOI
https://doi.org/10.1007/s40429-024-00564-0

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.